GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."
Pfizer and Teva's settlement puts generic Celebrex on the market by December.
Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.
Complete data sets have prompted researchers to say Tamilflu and Relenza fail at their key reason for being: preventing flu pandemics.
Phase-II results indicate Merck's all-in-one HCV oral could put pressure on Gilead.
The FDA issued an official halt, five days after Halozyme stopped the Phase-II trial because of patient stroke information.
The drugmaker is accused of burying cancer risks associated with the diabetes medication.
The regulator has put off the inhaled insulin's PDUFA date by three months.
Phase-III results prompted the drugmaker to pursue a third-quarter filing.
The announcement will create the fifth largest generics drug maker, reports Reuters.